<DOC>
	<DOCNO>NCT01555918</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic property isavuconazole ( BAL4815 ) cleavage product ( BAL8728 ) ass safety tolerability single-dose steady state ( multiple-dose ) administration isavuconazole BAL8557 healthy Chinese subject .</brief_summary>
	<brief_title>A Study Assess Safety Pharmacokinetics Isavuconazole Healthy Chinese Volunteers</brief_title>
	<detailed_description>This two part study : Part 1 : On Day 1 , Period 1 , subject receive single dose isavuconazole orally intravenously accord treatment sequence allocation . Subjects remain resident unit order collect blood pharmacokinetics ( PK ) ass safety test . They release morning Day 15 collection blood safety test . Subjects washout period 2 week return unit Day -1 Period 2 ( Day 29 ) . Subjects receive single dose isavuconazole orally intravenously ( opposite mode administration Period 1 ) . Subjects remain resident unit release morning Day 15 , Period 2 ( Day 44 ) collection blood test . Part 2 : Subjects allocate multiple intravenous ( IV ) ( Group 1 ) oral ( Group 2 ) dosing . On Day 1 , Group 1 receive multiple intravenous ( IV ) dose isavuconazole 2-hour infusion , three time day ( TID ) 8 hour dose 2 day follow isavuconazole 2-hour infusion every day ( QD ) 10 day . Group 2 receive multiple oral ( PO ) dose isavuconazole TID 8 hour dose 2 day follow isavuconazole PO QD 10 day . Subjects Group 1 2 remain resident unit order collect blood urine PK evaluation assess safety test . They release morning Day 26 collection blood test .</detailed_description>
	<criteria>The subject weigh least 50 kg , body mass index 19 24 kg/m2 inclusive . The subject 's 12lead electrocardiogram ( ECG ) normal The subject 's physical examination clinical laboratory test result within normal limit If female , subject agree sexual abstinence , surgically sterile , postmenopausal ( define least 2 year without menses ) , use medically acceptable doublebarrier method ( e.g . spermicide diaphragm , spermicide condom ) prevent pregnancy agree continue use method Screening end study ; lactate pregnant document negative serum pregnancy test If male , subject agree sexual abstinence , surgically sterile , use medically acceptable method prevent pregnancy study period . The subject agree comply diet smoking restriction prior entry clinical unit , confinement end study . The subject good venous access . The subject history clinically significant cardiac , endocrine , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy exception nonmelanoma skin cancer . The subject history gastrointestinal tract surgery . The subject know suspected hypersensitivity isavuconazole , azole class compound component study drug . The subject history consume 14 unit alcoholic beverage per week , history drug alcohol abuse within past 2 year positive screen alcohol drug abuse/illegal drug ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) . The subject use tobacco contain product nicotine containing product 5 cigarettes/day equivalent amount tobacco . The subject positive human immunodeficiency virus antibody Treponema pallidum . The subject positive hepatitis C antibody hepatitis B antigen The subject consume 1 liter tea coffee per day anticipate inability abstain caffeine alcohol use 48 hour prior clinic admission Day 1 throughout duration study ; grapefruit , Seville oranges , star fruit , product contain item 72 hour prior clinic admission Day 1 throughout duration study . The subject vaccinate within 30 day treatment prescription drug overthecounter medication ( include complementary alternative medicine ) within 14 day prior Checkin ( Day 1 ) , exception paracetamol 2g/day 4 days/week ( depot preparation prohibit ) . The subject participate clinical trial within 2 month prior study drug administration . The subject donate significant blood loss 200 mL , receive transfusion blood blood product within 2 month prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Isavuconazole</keyword>
	<keyword>BAL4815</keyword>
	<keyword>BAL8728</keyword>
	<keyword>BAL8557</keyword>
</DOC>